格列卫治疗慢性粒细胞白血病进展期的临床疗效观察(2)
 |
| 第1页 |
参见附件(1231KB，2页)。
但因格列卫不能逆转疾病基因,只能延长患者的生存期,并不能最终治愈,故达遗传或分子效应后仍需长期坚持服药,且价格极为昂贵,病人往往会因为经济问题自行减量或停药。另有不少文献报道在急变期患者,最终均出现耐药而失效。而我们由于例数尚少,用药时间较短,从现有治疗观察过程,初步认为格列卫治疗CML进展期患者,疗效确切、毒性少、安全性大,近期疗效满意,但其远期疗效如何,应通过分析相关因素对疗效及预后的影响,进一步积累、总结较多的病例来证实。
[参考文献]
[1] Odwyer ME,Mauro MJ,Druker BJ. Recent advancement of chronic myelogenous leukemia[J]. Annu Rev Med,2002,53:369-381.
[2] 张之南. 血液病诊断及疗效标准[M]. 第2版. 北京:科学出版社,1998:219 -228.
[3] Dru Ker BJ,Tal Paz M,Resta DJ,et al. Eifficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia[J]. N Engl J Med,2001,344:1031-1037.
[4] Kantarjia HM,Cortes JE,O’Brien S,et al. Imatinib mesylate(STI571)therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase[J]. Blood,2002,99(10):35471.
[5] Hehlmann R,Heimpel H,Hasfold J,et al. Randomized comparison of interferon αwith busulfan and hydroxyurea in chronic myelogenous leukemia[J]. Blood,1994,84:4064-4077.
[6] Clarkson B,Strife A,Wisnieuski D,et al. Chronic myelogenous leukemia as a paradigm of earycancer and possible curatine strategies[J]. Leukemia,2003,17:1211-1262.
[7] Dru Ker BJ. Imatinib alone and combination for chronic myeloid leukemia[J]. Semin Hematol,2003,40:50-58.
(收稿日期:2010-01-28)
您现在查看是摘要介绍页，详见PDF附件(1231KB，2页)。